The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.
The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.
Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.
AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga.
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.